195 related articles for article (PubMed ID: 26967642)
41. [Alterations in erythrocytic oligomeric alpha-synuclein in patients with Parkinson's disease and multiple system atrophy].
Yan XM; Li PJ; Li W; Wang XM; Yu S
Zhonghua Yi Xue Za Zhi; 2023 Oct; 103(37):2933-2939. PubMed ID: 37752052
[No Abstract] [Full Text] [Related]
42. Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected.
Gómez JM; Maravall FJ; Gómez N; Navarro MA; Casamitjana R; Soler J
Clin Endocrinol (Oxf); 2003 Feb; 58(2):213-9. PubMed ID: 12580938
[TBL] [Abstract][Full Text] [Related]
43. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.
Iglesias P; Díez JJ; Fernández-Reyes MJ; Méndez J; Bajo MA; Aguilera A; Selgas R
Clin Endocrinol (Oxf); 2004 Jun; 60(6):741-9. PubMed ID: 15163339
[TBL] [Abstract][Full Text] [Related]
44. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.
Eidson LN; Kannarkat GT; Barnum CJ; Chang J; Chung J; Caspell-Garcia C; Taylor P; Mollenhauer B; Schlossmacher MG; Ereshefsky L; Yen M; Kopil C; Frasier M; Marek K; Hertzberg VS; Tansey MG
J Neuroinflammation; 2017 Aug; 14(1):164. PubMed ID: 28821274
[TBL] [Abstract][Full Text] [Related]
45. [Associations of serum neuromarkers with clinical features of Parkinson's disease].
Nikitina MA; Koroleva ES; Brazovskaya NG; Boyko AS; Levchuk LA; Ivanova SA; Alifirova VM
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):145-152. PubMed ID: 38676689
[TBL] [Abstract][Full Text] [Related]
46. Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease.
Godau J; Knauel K; Weber K; Brockmann K; Maetzler W; Binder G; Berg D
Arch Neurol; 2011 Jul; 68(7):925-31. PubMed ID: 21747033
[TBL] [Abstract][Full Text] [Related]
47. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
[TBL] [Abstract][Full Text] [Related]
48. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).
Prakash N; Caspell-Garcia C; Coffey C; Siderowf A; Tanner CM; Kieburtz K; Mollenhauer B; Galasko D; Merchant K; Foroud T; Chahine LM; Weintraub D; Casaceli C; Dorsey R; Wilson R; Herzog M; Daegele N; Arnedo V; Frasier M; Sherer T; Marek K; Frank S; Jennings D; Simuni T; ; ; ; ;
Parkinsonism Relat Disord; 2019 May; 62():201-209. PubMed ID: 30738748
[TBL] [Abstract][Full Text] [Related]
49. Possible roles of insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer.
Jiang B; Zhang X; Du LL; Wang Y; Liu DB; Han CZ; Jing JX; Zhao XW; Xu XQ
World J Gastroenterol; 2014 Feb; 20(6):1608-13. PubMed ID: 24587638
[TBL] [Abstract][Full Text] [Related]
50. Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease.
Ng ASL; Tan YJ; Lu Z; Ng EY; Ng SYE; Chia NSY; Setiawan F; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
Aging (Albany NY); 2020 Jan; 12(2):1488-1495. PubMed ID: 31932518
[TBL] [Abstract][Full Text] [Related]
51. Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology.
Boertien JM; van der Zee S; Chrysou A; Gerritsen MJJ; Jansonius NM; Spikman JM; van Laar T;
BMC Neurol; 2020 Jun; 20(1):245. PubMed ID: 32534583
[TBL] [Abstract][Full Text] [Related]
52. Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults.
Mattsson A; Svensson D; Schuett B; Osterziel KJ; Ranke MB
Growth Horm IGF Res; 2008 Dec; 18(6):506-16. PubMed ID: 18550406
[TBL] [Abstract][Full Text] [Related]
53. Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity.
Tong M; Dong M; de la Monte SM
J Alzheimers Dis; 2009; 16(3):585-99. PubMed ID: 19276553
[TBL] [Abstract][Full Text] [Related]
54. IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population.
van den Beld AW; Carlson OD; Doyle ME; Rizopoulos D; Ferrucci L; van der Lely AJ; Egan JM
Eur J Endocrinol; 2019 Feb; 180(2):109-116. PubMed ID: 30475224
[TBL] [Abstract][Full Text] [Related]
55. Serum levels of lipocalin-2 in patients with Parkinson's disease.
Xiong M; Qian Q; Liang X; Wei YD
Neurol Sci; 2022 Mar; 43(3):1755-1759. PubMed ID: 34455500
[TBL] [Abstract][Full Text] [Related]
56. High insulin-like growth factor-1 in patients with bipolar I disorder: a trait marker?
Kim YK; Na KS; Hwang JA; Yoon HK; Lee HJ; Hahn SW; Lee BH; Jung HY
J Affect Disord; 2013 Nov; 151(2):738-743. PubMed ID: 24012102
[TBL] [Abstract][Full Text] [Related]
57. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation.
Juul A; Dalgaard P; Blum WF; Bang P; Hall K; Michaelsen KF; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Aug; 80(8):2534-42. PubMed ID: 7543116
[TBL] [Abstract][Full Text] [Related]
58. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
59. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity.
Gleeson HK; Lissett CA; Shalet SM
J Clin Endocrinol Metab; 2005 Feb; 90(2):1061-7. PubMed ID: 15522943
[TBL] [Abstract][Full Text] [Related]
60. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
Williams-Gray CH; Wijeyekoon R; Yarnall AJ; Lawson RA; Breen DP; Evans JR; Cummins GA; Duncan GW; Khoo TK; Burn DJ; Barker RA;
Mov Disord; 2016 Jul; 31(7):995-1003. PubMed ID: 26999434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
